Osteogenesis and Therapeutic Strategies for Osteoporosis

Osteogenesis is the complex, tightly regulated process by which bone is continually remodelled through the coordinated activity of osteoblasts, which synthesise new matrix and orchestrate mineralisation, and osteoclasts, which resorb aged or damaged bone. In healthy adults, bone formation and resorption are balanced to maintain skeletal integrity; osteoporosis arises when resorption outpaces formation, leading to reduced bone mass, microarchitectural deterioration and increased fracture risk. Key molecular pathways governing osteogenesis include WNT/β-catenin, BMP/SMAD and RANK/RANKL/OPG, which control differentiation of mesenchymal stem cells into osteoblasts, matrix production and osteoclast regulation. Current pharmacological interventions encompass antiresorptives (bisphosphonates, RANKL inhibitors) and anabolic agents (parathyroid hormone analogues, sclerostin antibodies), while emerging strategies focus on targeted modulation of signalling cascades, cell‐based therapies using mesenchymal stem cells or their exosomes, biomaterial scaffolds for localised growth factor delivery, and lifestyle approaches such as tailored nutrition and exercise regimens. Novel small molecules and biologics that fine-tune osteogenic signalling hold promise for more effective, long-lasting restoration of bone strength with favourable safety profiles.

Research from Nature Portfolio

Recent studies have applied single-cell transcriptomics to map the osteoblastic lineage, uncovering a distinct preosteoblast subpopulation characterised by high expression of Sp7 and low Col1a1, implicating this niche in matrix organisation and mineral deposition. In parallel, a novel small-molecule agonist targeting LRP5/6 receptors has been shown to amplify canonical WNT signalling, restoring bone mass and improving cortical microarchitecture in ovariectomised animal models. Furthermore, osteocyte-derived exosomes enriched in miRNA-29a were found to promote osteoblast differentiation and suppress osteoclastogenesis by downregulating the WNT antagonist DKK1, highlighting intercellular vesicle communication as a potential anabolic avenue.

Osteogenesis and Therapeutic Strategies for Osteoporosis publication trend

The graph below shows the total number of articles in osteogenesis and therapeutic strategies for osteoporosis across all publications each year (not limited to Nature Index journals).

Technical terms

Osteogenesis: The physiological formation of new bone, involving osteoblast differentiation, extracellular matrix deposition and mineralisation.

Osteoclastogenesis: The process of differentiation and activation of osteoclasts from haematopoietic precursors, leading to bone resorption.

WNT/β-catenin signalling: A key pathway regulating osteoblast proliferation and maturation by stabilising β-catenin and driving target gene transcription.

RANKL: A cytokine produced by osteoblasts and stromal cells that binds to RANK on monocyte precursors to trigger osteoclast differentiation.

SMAD proteins: Intracellular effectors of BMP and TGF-β signalling that translocate to the nucleus to regulate osteogenic gene expression.

References

1. Sword Bean (Canavalia gladiata) Pods Induce Differentiation in MC3T3-E1 Osteoblast Cells by Activating the BMP2/SMAD/RUNX2 Pathway. Nutrients (2023).
2. Ginsenoside compound-K attenuates OVX-induced osteoporosis via the suppression of RANKL-induced osteoclastogenesis and oxidative stress. Natural Products and Bioprospecting (2023).
3. Effects of ginsenosides on bone remodelling for novel drug applications: a review. Chinese Medicine (2020).